T-Cell Response and Antibody Production Induced by the COVID-19 Booster Vaccine in Japanese Chronic Kidney Disease Patients Treated with Hemodialysis
Ayumi Yoshifuji,
Masataro Toda,
Munekazu Ryuzaki,
Emi Oyama,
Kan Kikuchi,
Toru Kawai,
Ken Sakai,
Masayoshi Koinuma,
Kazuhiko Katayama,
Takashi Yokoyama,
Yuki Uehara,
Norio Ohmagari,
Yoshihiko Kanno,
Hirofumi Kon,
Toshio Shinoda,
Yaoko Takano,
Junko Tanaka,
Kazuhiko Hora,
Yasushi Nakazawa,
Naoki Hasegawa,
Norio Hanafusa,
Fumihiko Hinoshita,
Keita Morikane,
Shu Wakino,
Hidetomo Nakamoto,
Yoshiaki Takemoto
Affiliations
Ayumi Yoshifuji
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Masataro Toda
Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, Tokyo 108-0073, Japan
Munekazu Ryuzaki
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Emi Oyama
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Kan Kikuchi
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Toru Kawai
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Ken Sakai
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Masayoshi Koinuma
Faculty of Pharmaceutical Sciences, Teikyo Heisei University, Tokyo 164-8530, Japan
Kazuhiko Katayama
Laboratory of Viral Infection Control, Ōmura Satoshi Memorial Institute, Graduate School of Infection Control Sciences, Kitasato University, Tokyo 108-8641, Japan
Takashi Yokoyama
Department of Infectious Diseases, Keio University School of Medicine, Tokyo 160-8582, Japan
Yuki Uehara
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Norio Ohmagari
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yoshihiko Kanno
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Hirofumi Kon
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Toshio Shinoda
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yaoko Takano
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Junko Tanaka
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Kazuhiko Hora
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yasushi Nakazawa
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Naoki Hasegawa
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Norio Hanafusa
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Fumihiko Hinoshita
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Keita Morikane
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Shu Wakino
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Hidetomo Nakamoto
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Yoshiaki Takemoto
Infection Control Committee, The Japanese Society for Dialysis Therapy, Tokyo 113-0033, Japan
Humoral and cellular responses are critical in understanding immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Here, we evaluated these responses in hemodialysis (HD) patients after the booster vaccination. SARS-CoV-2 immunoglobulin (IgG) levels, neutralizing antibody titers, and the T-SPOT®.COVID test (T-SPOT) were measured prior to, three weeks after, and three months after the booster administration. The HD group had significantly higher SARS-CoV-2 IgG levels and neutralizing antibody titers against the original strain at three weeks and three months after the booster vaccination compared to the control group, albeit the HD group had lower SARS-CoV-2 IgG levels and neutralizing antibody titers before the booster administration. Moreover, the HD group had significantly higher T-SPOT levels at all three time points compared to the control group. The HD group also had significantly higher local and systemic adverse reaction rates than the control group. By booster vaccination, HD patients could acquire more effective SARS-CoV-2-specific humoral and cellular immunity than the control group.
